| Literature DB >> 27721920 |
Kaveh Hajifathalian1, Annette Humberson1, Mohamad A Hanouneh1, David S Barnes1, Zubin Arora1, Nizar N Zein1, Bijan Eghtesad1, Dympna Kelly1, Ibrahim A Hanouneh1.
Abstract
AIM: To evaluate risk of recidivism on a case-by-case basis.Entities:
Keywords: Alcohol-induced disorders; Alcoholic liver cirrhosis; Liver transplantation; Mortality; Survival
Year: 2016 PMID: 27721920 PMCID: PMC5037328 DOI: 10.4254/wjh.v8.i27.1149
Source DB: PubMed Journal: World J Hepatol
Ohio Solid Organ Transplantation Consortium medically urgent except criteria
| Low-risk | 1 mo confirmed abstinence, a signed contract and commitment to begin a rehabilitation program and finish it either before or after transplant |
| No previous failure with substance rehabilitation; never been told that substance was affecting health; and good social support | |
| Medium-risk | Three month confirmed abstinence, a signed contract and commitment to begin a rehabilitation program and/or finish it either before or after transplant |
| One or more failures with rehabilitation; and minimal support system | |
| High-risk | Two or more failures to remain abstinent despite medical complication |
| Refusal to sign contract | |
| Minimal to poor social support | |
| Must complete standard criteria treatment plan, not eligible for an exception | |
| Other barriers | No insight into their alcohol use consequences |
| No recognition that alcohol caused their liver failure | |
| Refusal to start treatment | |
| No sober support network |
Figure 1Selection of patients with alcoholic liver disease for liver transplantation based on Ohio Solid Organ Transplantation Consortium Criteria. OSOTC: Ohio Solid Organ Transplantation Consortium.
Characteristics of study patients and controls
| At listing | ||
| 36 | 72 | |
| Age, median (IQR) | 58 (14) | 60 (11) |
| Male, | 23 (64) | 46 (64) |
| INR, median (IQR) | 1.8 (0.6) | 1.9 (0.7) |
| Total Bilirubin, median (IQR) | 8.9 (19.3) | 5 (7.7) |
| Creatinine, median (IQR) | 2.1 (2.4) | 1.5 (2) |
| Albumin, median (IQR) | 3.2 (0.9) | 2.9 (1) |
| MELD, median (IQR) | 27 (11) | 24 (11) |
| At transplant | ||
| 19 | 38 | |
| Age, median (IQR) | 56 (17) | 55 (13) |
| Male, | 13 (68) | 26 (68) |
| INR, median (IQR) | 1.6 (0.5) | 1.9 (0.8) |
| Total Bilirubin, median (IQR) | 8.3 (12.1) | 6 (5.7) |
| Creatinine, median (IQR) | 2.6 (2.9) | 1.3 (1.3) |
| Albumin, median (IQR) | 2.9 (0.8) | 2.8 (1) |
| MELD, median (IQR) | 24 (13) | 25 (9) |
IQR: Inter-quartile range; INR: International normalized ratio; MELD: Model for end stage liver disease.
Follow-up details of listed and transplanted patients and controls
| After listing | |||
| No. listed | 36 | 72 | |
| No. transplanted (%) | 19 (53) | 41 (57) | 0.687 |
| Waiting time for transplant, d, median (IQR) | 19 (7-65) | 21 (5-54) | 0.648 |
| After transplant | |||
| No. transplanted | 19 | 38 | |
| Follow-up after transplant, months, median (IQR) | 41 (29-58) | 37 (14-61) | |
| 1-yr survival, % ± SE | 90 ± 7 | 92 ± 5 | 0.837 |
| 5-yr survival, % ± SE | 73 ± 12 | 77 ± 8 |
χ2 test;
P-value for patient vs control time to transplant Cox proportional hazards model;
Log-Rank test. IQR: Inter-quartile range; SE: Standard error.
Figure 2Kaplan-meier estimates of survival after liver transplant in the 19 study patients and the 38 matched controls.